80 related articles for article (PubMed ID: 17889113)
1. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis.
Casanovas-Taltavull T; Baliellas C; Llobet M; Cruzado JM; Castellote J; Casanova A; Niubó J; Valls C; Serrano T
Transplant Proc; 2007 Sep; 39(7):2125-7. PubMed ID: 17889113
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
Kokoglu OF; Uçmak H; Hosoglu S; Cetinkaya A; Kantarceken B; Buyukbese MA; Isik IO
J Gastroenterol Hepatol; 2006 Mar; 21(3):575-80. PubMed ID: 16638102
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients.
Ucmak H; Kokoglu OF; Hosoglu S; Dogan E; Sayarlioglu H; Kuzhan N; Isik IO
Ren Fail; 2008; 30(2):227-32. PubMed ID: 18300126
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.
Chan TM; Ho SK; Tang CS; Tse KC; Lam MF; Lai KN; Yung S
Nephrology (Carlton); 2007 Feb; 12(1):11-7. PubMed ID: 17295655
[TBL] [Abstract][Full Text] [Related]
5. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
van Leusen R; Adang RP; de Vries RA; Cnossen TT; Konings CJ; Schalm SW; Tan AC
Nephrol Dial Transplant; 2008 Feb; 23(2):721-5. PubMed ID: 18042614
[TBL] [Abstract][Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.
Wang KL; Xing HQ; Zhao H; Liu JW; Gao DL; Zhang XH; Yao HY; Yan L; Zhao J
World J Gastroenterol; 2014 Apr; 20(14):4071-5. PubMed ID: 24744598
[TBL] [Abstract][Full Text] [Related]
10. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of chronic hepatitis C virus infection in hemodialysis patients].
Kaya S
Mikrobiyol Bul; 2008 Jul; 42(3):525-34. PubMed ID: 18822900
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey.
Kose S; Gurkan A; Akman F; Kelesoglu M; Uner U
J Gastroenterol; 2009; 44(4):353-8. PubMed ID: 19277451
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis.
Amarapurkar DN; Patel ND; Kirpalani AL
Trop Gastroenterol; 2007; 28(1):16-8. PubMed ID: 17896604
[TBL] [Abstract][Full Text] [Related]
15. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
16. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
Antaki N; Hermes A; Hadad M; Ftayeh M; Antaki F; Abdo N; Kebbewar K
J Viral Hepat; 2008 May; 15(5):383-6. PubMed ID: 18086180
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
20. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
